AbbVie (NYSE:ABBV - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, July 31st. Analysts expect AbbVie to post earnings of $3.24 per share and revenue of $14.93 billion for the quarter.
AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same period in the prior year, the firm earned $2.31 earnings per share. AbbVie's revenue was up 8.4% on a year-over-year basis. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.
AbbVie Stock Up 0.4%
Shares of AbbVie stock traded up $0.68 during trading hours on Thursday, reaching $191.26. The company's stock had a trading volume of 4,851,902 shares, compared to its average volume of 6,321,012. AbbVie has a one year low of $163.81 and a one year high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. The stock's fifty day simple moving average is $186.95 and its two-hundred day simple moving average is $189.20. The company has a market capitalization of $337.83 billion, a P/E ratio of 81.39, a P/E/G ratio of 1.24 and a beta of 0.48.
AbbVie Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a dividend of $1.64 per share. The ex-dividend date is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.43%. AbbVie's dividend payout ratio (DPR) is currently 279.15%.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on ABBV shares. Evercore ISI lifted their price objective on AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Citigroup boosted their price target on shares of AbbVie to $205.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Morgan Stanley boosted their price objective on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a report on Monday, April 28th. Finally, Bank of America upped their price objective on AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and an average target price of $211.29.
Read Our Latest Stock Analysis on AbbVie
Institutional Trading of AbbVie
A hedge fund recently raised its stake in AbbVie stock. Brighton Jones LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 17.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,912 shares of the company's stock after buying an additional 3,401 shares during the period. Brighton Jones LLC's holdings in AbbVie were worth $4,072,000 as of its most recent filing with the Securities & Exchange Commission. 70.23% of the stock is owned by institutional investors.
AbbVie Company Profile
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Stories
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
